SPY457.40+6.90 1.53%
DIA346.61+6.15 1.81%
IXIC15,381.32+127.27 0.83%

SVB Leerink Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $40

SVB Leerink analyst Marc Goodman maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $34 to $40.

Benzinga · 11/11/2021 04:57
SVB Leerink analyst Marc Goodman maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $34 to $40.